PPARG expression is downregulated in the basal subtype of bladder cancer, and amplification of the PPARG gene or activating mutations in RXR, the PPARG binding partner, are present in ~17% of luminal tumors22,79,80, which has led to the suggestion that PPARG drives luminal tumor formation. The gene discussed is PPARG; the disease is urinary bladder carcinoma.